Leflunomide

證據等級: L5

預測適應症: 2 個

Leflunomide: From Autoimmune Disease (DMARD) to Brachydactyly-Syndactyly Syndrome

One-Sentence Summary

Leflunomide is an immunosuppressant belonging to the DMARD class, acting via DHODH inhibition to suppress lymphocyte proliferation; formal original indication data is not available in this Evidence Pack. The TxGNN model predicts it may be effective for Brachydactyly-Syndactyly Syndrome, however there are currently 0 clinical trials and 0 publications supporting this direction — the evidence base is purely model-generated with no empirical support.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack (DMARD class, immunosuppressive)
Predicted New Indication	Brachydactyly-Syndactyly Syndrome
TxGNN Prediction Score	99.93%
Evidence Level	L5
Italy Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on information referenced in the repurposing rationale, Leflunomide is an immunosuppressant that inhibits DHODH (dihydroorotate dehydrogenase), thereby limiting pyrimidine synthesis and reducing lymphocyte proliferation. It belongs to the DMARD (disease-modifying antirheumatic drug) class.

Brachydactyly-syndactyly syndrome is a rare congenital skeletal developmental disorder, primarily caused by mutations in genes such as HRAS or FGFR2, which disrupt digit bone formation during embryogenesis. This is a structural genetic defect — the anatomical abnormalities are established before birth, and post-natal drug administration cannot reverse them.

The mechanistic link between Leflunomide's DHODH inhibition and this congenital syndrome is considered extremely weak. Leflunomide's cell-proliferation suppression mechanism provides no plausible corrective pathway for a fixed skeletal malformation. Furthermore, Leflunomide carries well-documented teratogenic toxicity (FDA Pregnancy Category X), meaning any use during embryogenesis — the only window where the pathology develops — is strictly contraindicated. There is no credible treatment hypothesis to support this repurposing direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Italy Market Information

Leflunomide is not currently marketed in Italy. No marketing authorizations were identified in the regulatory database (total licenses: 0).

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Note: TFDA/AIFA package insert warnings and contraindications were flagged as a blocking data gap (DG001) in this Evidence Pack and could not be extracted. Safety assessment cannot be completed until this data is retrieved.

Conclusion and Next Steps

Decision: Hold

Rationale: There are zero clinical trials and zero published studies supporting Leflunomide for brachydactyly-syndactyly syndrome, and the mechanistic link between DHODH inhibition and a congenital skeletal structural defect is considered scientifically implausible. The high TxGNN score (99.93%) reflects model inference only and is not corroborated by any real-world evidence.

To proceed, the following is needed:

A credible mechanistic hypothesis explaining how post-natal DHODH inhibition could benefit a fixed congenital skeletal malformation
Preclinical in vitro or in vivo evidence demonstrating any relevant biological activity in this indication
Full MOA data from DrugBank (DG002) to complete mechanistic analysis
TFDA/AIFA package insert warnings and contraindications (DG001) for complete safety profiling
Consideration of whether any adjacent rare disease indication (e.g., inflammatory or autoimmune bone disease) might be a more scientifically grounded repurposing target for Leflunomide
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.